New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
16:31 EDTT, HPQ, HD, CRM, PETM, CPB, DKS, GM, LOCK, LO, RAI, AGN, VRX, AZN, PFE, DTV, DLTRMarket ends week higher after Fed minutes, housing data
Stocks finished the week higher after Fed minutes revealed that the central bank does not see inflation as a near-term threat and several economic data points were better than expected. MACRO NEWS: The minutes of the Fed's last meeting stated that committee members expect inflation to remain well below the central bank's 2% objective, adding that the Fed does not believe that it currently faces a trade-off between its employment and inflation objectives... Reports on existing home sales and new home sales in April both showed monthly gains, while a U.S. manufacturing index beat expectations. The index of leading indicators for April was in-line with expectations, while jobless claims were slightly worse than expected. An index of Chinese manufacturing, reported by HSBC, came in significantly above expectations and reached a five month high, despite still indicating contraction in the sector. COMPANY NEWS: AT&T (T) confirmed last weekend that it had agreed to acquire DirecTV (DTV) for $95.00 per share, including $28.50 per share in cash and $66.50 per share in AT&T stock. Also last weekend, Pfizer (PFE) raised its bid for AstraZeneca (AZN), but the U.K. drugmaker again rejected this "final" takeover proposal. In other M&A news, Valeant (VRX) stated that it would sweeten its previous bid for Allergan (AGN), but clarified that the new bid would not be an all-cash offer. Meanwhile, Reuters reported that cigarette maker Reynolds American (RAI) was in advanced talks to acquire its peer, Loriillard (LO)... Lifelock (LOCK), which provides identify theft protection services, tumbled after disclosing that it would temporarily suspend its Wallet mobile application because it is not fully compliant with applicable payment card industry security standards... General Motors (GM) shares fell after the company announced that it was recalling an additional 2.42M vehicles in four separate U.S. recalls. The automaker added $200M to the charge it expects to take in Q2 related to its recalls, bringing the total potential charge up to $400M... Dick's Sporting Goods (DKS), Campbell Soup (CPB), and PetSmart (PETM) were among the companies that dropped after announcing their earnings results. Meanwhile, Home Depot (HD), Hewlett-Packard (HPQ), and Dollar Tree (DLTR) were among the companies whose shares rose following their quarterly reports. INDEXES: The Dow was up 0.7% to 16,606.27, the S&P 500 was up 1.2% to 1,900.53, and the Nasdaq was up 2.33% to 4,185.81.
News For T;DTV;PFE;AZN;VRX;AGN;RAI;LO;LOCK;GM;DKS;CPB;PETM;CRM;HD;HPQ;DLTR From The Last 14 Days
Check below for free stories on T;DTV;PFE;AZN;VRX;AGN;RAI;LO;LOCK;GM;DKS;CPB;PETM;CRM;HD;HPQ;DLTR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>
September 16, 2014
14:33 EDTAZNNektar price target raised to $20 from $18 at Brean Capital
Subscribe for More Information
13:09 EDTGMGeneral Motors to add third shift, 750 jobs at Wentzville Assembly plant
Subscribe for More Information
12:37 EDTAZNNektar reports FDA approval of MOVANTIK for treatment of OIC
Nektar Therapeutics (NKTR) reported that partner AstraZeneca (AZN) announced that the FDA approved MOVANTIK tablets as the first once-daily oral peripherally-acting mu-opioid receptor antagonist medication for the treatment of opioid-induced constipation, or OIC, in adult patients with chronic, non-cancer pain. In line with the recommendation from the FDA Anesthetic and Analgesic Drug Products Advisory Committee that took place in June, AstraZeneca has agreed to conduct a post-marketing, observational epidemiologic cardiovascular safety study for MOVANTIK. MOVANTIK is expected to be available to patients in the first half of 2015. MOVANTIK is currently a schedule II controlled substance because it is structurally related to noroxymorphone. During the review of the New Drug Application, the FDA evaluated the abuse potential of MOVANTIK and the approved labelling indicates that MOVANTIK has no risk of abuse or dependency. AstraZeneca submitted a petition for the descheduling of MOVANTIK to the U.S. Drug Enforcement Administration, or DEA, in March 2012, which was accepted for review and will be considered by the DEA as part of the process for addressing the descheduling request.
12:19 EDTGMGM ups U.S. mid-sized pickup production, Reuters says
Subscribe for More Information
11:51 EDTAZN, AGN, PFE, VRXOECD looks to close tax loopholes with new proposals
Subscribe for More Information
10:19 EDTAZNFDA approves Movantik with requirement for cardiovascular risk study
Subscribe for More Information
08:46 EDTGMGeneral Motors concerns about Ford's new F-Series are overdone, says Goldman
Goldman believes concerns about Ford's new F-Series impact on General Motors is overdone. The analyst said investors are underestimating F-150 capacity constraints if the launch is successful, which will limit General Motors share loss.
08:00 EDTAZNFDA PDUFA Date for Nektar and AstraZeneca''s Movantik is September 16, 2014
07:31 EDTAZNEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:27 EDTTBofA/Merrill to hold a conference
Subscribe for More Information
07:26 EDTGMUltima Media to hold a conference
Subscribe for More Information
07:24 EDTDKSDick's Sporting announces retirement of president and COO Joseph Schmidt
Subscribe for More Information
07:19 EDTHD, PFECompanies' share buybacks at fasttest clip since 2007, WSJ reports
Companies are buying back their own shares at its fastest pace since the financial crisis to fuel a stock rally, reports the Wall Street Journal. According to Birinyi Associates, companies have bought back $338.3B of stock in 1H14, the most since 2007. Citing an analysis by Barclays, companies with the largest buyback programs by dollar value have outperformed the broader market by 20% since 2008. Reference Link
07:02 EDTAZNEli Lilly and AstraZeneca to co-develop and commercialize AZD3293
Subscribe for More Information
06:54 EDTGMGM's Opel realigns Russian operations
Subscribe for More Information
06:43 EDTGMNHTSA exec knocks GM for distorted recall protocol, Reuters says
The acting administrator of the National Highway Traffic Safety Administration David Friedman said that GM placed its own reputation before customer safety when it did not quickly report and recall vehicles that are now connected to at least 19 deaths, according to Reuters, citing comments from Friedman. Friedman said that he has been meeting with top worldwide car manufactures to develop a "new normal" for safety recall protocol. Reference Link
06:38 EDTGMGM Opel unit to reduce production in Russia, Reuters says
Subscribe for More Information
06:30 EDTGMNHTSA chief calls for 'new normal' for recalls, Detroit News reports
Subscribe for More Information
06:27 EDTAZNAstraZeneca, Eli Lilly to jointly develop, commercialize AZD3293
AstraZeneca (AZN) and Eli Lilly (LLY) announced an agreement to jointly develop and commercialize AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in development as a potential treatment for Alzheimer's disease. AZD3293 has been shown in Phase I studies to significantly and dose-dependently reduce levels of amyloid beta in the cerebro-spinal fluid of Alzheimer's patients and healthy volunteers. AstraZeneca announced earlier in 2014 its plan to move AZD3293 into registration trials. Under the terms of the agreement, Lilly will pay AstraZeneca up to $500M in development and regulatory milestone payments. AstraZeneca expects to receive the first milestone payment of $50M in the 1H15. The companies will share all future costs equally for the development and commercialization of AZD3293, as well as net global revenues post-launch. AstraZeneca and Lilly aim to progress AZD3293 rapidly into a Phase II/III clinical trial in patients with early Alzheimer's disease. Lilly will lead clinical development, working with researchers from AstraZeneca's Innovative Medicines Unit for neuroscience, while AstraZeneca will be responsible for manufacturing. The companies will take joint responsibility for commercialization of AZD3293. The agreement is subject to customary terms and conditions. It will have no impact on AstraZeneca's 2014 Core Earnings per Share.
05:37 EDTAGN, VRXValeant, Pershing Square, Allergan settle pending litigation before DE Court
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use